Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer by Javed, SR, Skolariki, A, Zameer, MZ, Lord, SR

Pharmacodynamic and pharmacokinetic markers for anti-angiogenic cancer therapy: Implications for dosing and selection of patients. by Morotti, M, Dass, P, Harris, AL, Lord, SR

Change in vision, visual disability, and health after cataract surgery. by Helbostad, J, Oedegaard, M, Lamb, S, Delbaere, K, Lord, SR, Sletvold, O

Assessment of physical activity in older people with and without cognitive impairment. by Hauer, K, Lord, SR, Lindemann, U, Lamb, S, Aminian, K, Schwenk, M

METFORMIN'S EFFECTS ON BREAST CANCER LIPID METABOLISM by Lord, SR, Collins, J, Fielding, B, Buffa, F, Karpe, F, Harris, A

METFORMIN'S EFFECTS ON BREAST CANCER LIPID METABOLISM by Lord, SR, Collins, J, Fielding, B, Buffa, F, Karpe, F, Harris, A

Fluciclovine is a potential imaging biomarker of glutamine utilisation in breast cancer by Teoh, EJ, Bridges, EM, Morotti, M, Zois, CE, Lord, SR, Gleeson, FV, Harris, AL

Self-reported chronic pain is associated with physical performance in older people leaving aged care rehabilitation by Pereira LS, Sherrington C, Ferreira ML, Tiedemann A, Ferreira PH, Blyth FM, Close JC, Taylor M, Lord SR

Get full text

New role of fat-free mass in cancer risk linked with genetic predisposition by Harris, BHL, Di Giovannantonio, M, Zhang, P, Harris, DA, Lord, SR, Allen, NE, Maughan, TS, Bryant, RJ, Harris, AL, Bond, GL, Buffa, FM

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and cape... by Thomas, A, Virdee, PS, Martin, E, Lord, SR, Falk, S, Anthoney, DA, Turkington, RC, Goff, M, Elhussein, L, Collins, L, Love, S, Moschandreas, J, Middleton, MR

Characterising ¹⁸F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging by Scott, NP, Teoh, EJ, Flight, H, Jones, BE, Niederer, J, Mustata, L, MacLean, GM, Roy, PG, Remoundos, DD, Snell, C, Liu, C, Gleeson, FV, Harris, AL, Lord, SR, McGowan, DR

Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer by Morotti, M, Bridges, E, Valli, A, Choudhry, H, Sheldon, H, Wigfield, S, Gray, N, Zois, C, Grimm, F, Jones, D, Teoh, EJ, Wei-Chen, C, Anastasiou, D, Haider, S, McIntyre, A, Goberdhan, DCI, Buffa, F, Harris, AL, Lord, SR

Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma by Carroll, TM, Chadwick, JA, Owen, RP, White, MJ, Kaplinsky, J, Peneva, I, Frangou, A, Xie, PF, Chang, J, Roth, A, Amess, B, James, SA, Rei, M, Fuchs, HS, McCann, KJ, Omiyale, AO, Jacobs, B-A, Lord, SR, Norris-Bulpitt, S, Dobbie, ST, Griffiths, L, Ramirez, KA, Ricciardi, T, Macri, MJ, Ryan, A, Venhaus, RR, Van den Eynde, BJ, Karydis, I, Schuster-Böckler, B, Middleton, MR, Lu, X

Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases by Pagnamenta, AT, Camps, C, Giacopuzzi, E, Taylor, JM, Hashim, M, Calpena, E, Kaisaki, PJ, Hashimoto, A, Yu, J, Sanders, E, Schwessinger, R, Hughes, JR, Lunter, G, Dreau, H, Ferla, M, Lange, L, Kesim, Y, Ragoussis, V, Vavoulis, DV, Allroggen, H, Ansorge, O, Babbs, C, Banka, S, Baños-Piñero, B, Beeson, D, Ben-Ami, T, Bennett, DL, Bento, C, Blair, E, Brasch-Andersen, C, Bull, KR, Cario, H, Cilliers, D, Conti, V, Davies, EG, Dhalla, F, Dacal, BD, Dong, Y, Dunford, JE, Guerrini, R, Harris, AL, Hartley, J, Hollander, G, Javaid, K, Kane, M, Kelly, D, Kelly, D, Knight, SJL, Kreins, AY, Kvikstad, EM, Lines, KE, Lord, SR, Lu, X, Marsden, B, Ormondroyd, E, Stevenson, M, Twigg, SRF, Uhlig, HH, Watkins, H, Schuh, AH, Wilkie, AOM, Taylor, JC